🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study

Recruitingn/aAges 24 Months - 59 MonthsAllPeter Steinmann
NCT06698510 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The proposed small-scale pilot studies are public health intervention studies implemented through established routine programs and services in the frame of the mass drug administration (MDA) campaigns in Côte d'Ivoire, Kenya and Uganda. In each country two most promising health intervention platforms were selected for pilot distribution of arpraziquantel 150mg (arPZQ). The aim of the small-scale pilot study is to assess the performance of different platforms for distributing arPZQ, a child-friendly formulation of praziquantel, to the target population (i.e., preschool-aged children (PSAC)) currently missed out in schistosomiasis treatment campaigns. The specific objectives of the pilot study are: * To assess the performance of different platforms for delivery of arPZQ to PSAC aged 24 to 59 months in terms of coverage, feasibility and acceptability * To determine social mobilization an

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
* Living in the designated implementation area since at least 6 months * Aged between 24 - 59 months * Informed consent available * No acute or chronic illness and/or inability to take oral medication * No reported history of seizures * No known allergic response to praziquantel
💊

What it tests

  • Arpraziquantel 150mg dispersible tablet
📍

Where

7 sites
Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU)
Abidjan, Côte d’Ivoire
Université Félix Hophouët-Boigny (UFHB), Département de sociologie
Abidjan, Côte d’Ivoire
Université Félix Hophouët-Boigny (UFHB), UFR Biosciences
Abidjan, Côte d’Ivoire
African Institute for Health and Development (AIHD)
Nairobi, Kenya
Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)
Nairobi, Kenya
Makerere University, Department of Sociology and Anthropology
Kampala, Uganda
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health
Kampala, Uganda
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy